BARDA paid $482m to get Fetroja made on US soil.
Japanese pharma Shionogi secured the contract under Project BioShield: $119m upfront, up to $363m more over multiple years, to build a US drug product manufacturing facility for cefiderocol, the gram-negative injectable antibiotic marketed as Fetroja. The drug cleared FDA in 2019 for complex urinary tract infections with little to no alternative treatment options, then got a 2020 label expansion to ventilator-associated and hospital-acquired bacterial pneumonia.
Here’s what BARDA actually bought: GlobalData forecasts Fetroja at $388m in global 2031 sales, with more than 60% ($237m) coming from the US. Compare that to the EU’s recent €30m ($35m) AMR commitment, and the US government’s bet looks like a different order of magnitude entirely.
The contract’s scope goes beyond the manufacturing buildout. Shionogi will use the capital to pursue pediatric indications for hospital-acquired and ventilator-associated bacterial pneumonia, plus hard-to-treat infections tied to “high priority biothreat pathogens” including Burkholderia pseudomallei and Yersinia pestis.
BARDA’s commitment isn’t new. It’s poured more than $2.7bn into antimicrobial development since 2010, helping six antibiotics clear FDA. Wellcome estimates AMR will kill 39 million people between 2025 and 2050.
The timing fits with trade policy too. Japan’s recent deal with the US set branded drug import tariffs at 15%, an 85% reduction from the 100% rate applied outside that arrangement. Shionogi’s domestic manufacturing now doubles as a tariff hedge.
No facility open date was disclosed.
— Diana Kowalski